



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

6421 03 17 19 2006

Re: TNKase  
Docket No. 01E-0098

The Honorable James. E. Rogan  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 1450  
Alexandria, VA 22313-1450

NOV 17 2003

Dear Director Rogan:

This is in regard to the patent term extension application for U.S. Patent No. 5,385,732 filed by Genetech, Inc. under 35 U.S.C. § 156. The patent claims TNKase (tenecteplase), BLA 99-0903.

In the September 27, 2001, issue of the Federal Register (66 Fed. Reg. 49392), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before February 26, 2002, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period. Due to an inadvertant error, the notice provided for a 150-day period for filing a due diligence petition rather than a 180-day period.

The 180-day period for filing a due diligence petition has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

*Jane A. Axelrad*

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Ginger R. Dreger  
Knobbe, Martens, Olson, & Bear, L.L.P.  
620 Newport Center Drive, 16th Floor  
Newport Beach, CA 92660

01E-0098

LET 4